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In 2017, Korean Society of Medical Oncology (KSMO) published the Korean man-
agement guideline of metastatic prostate cancer. This paper is the 2nd edition 
of the Korean management guideline of metastatic prostate cancer. We updated 
recent many changes of management in metastatic prostate cancer in this 2nd 
edition guideline. The present guideline consists of the three categories: man-
agement of metastatic hormone sensitive prostate  cancer; management of meta-
static castration resistant prostate  cancer; and clinical consideration for treating 
patients with metastatic prostate cancer. In category 1 and 2, levels of evidence 
(LEs) have been mentioned according to the general principles of evidence-based 
medicine. And grades of recommendation (GR) was taken into account the qual-
ity of evidence, the balance between desirable and undesirable effects, the values 
and preferences, and the use of resources and GR were divided into strong rec-
ommendations (SR) and weak recommendations (WR). A total of 16 key questions 
are selected. And we proposed recommendations and described key evidence for 
each recommendation. The treatment landscape of metastatic prostate cancer is 
changing very rapid and many trials are ongoing. To verify the results of the fu-
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INTRODUCTION
In 2017, the Korean Society of Medical Oncology (KSMO) 
published the Korean management guidelines for met-
astatic prostate cancer. Here, we present the second 
edition of the Korean management guidelines for met-
astatic prostate cancer, in which we have incorporated 
recent changes in metastatic prostate cancer manage-
ment. The questions addressed in this second edition 
of management guidelines can be classified into three 
categories: (1) management of metastatic hormone-sen-
sitive prostate cancer (mHSPC); (2) management of met-
astatic castration-resistant prostate cancer (CRPC); and 
(3) clinical considerations for the treatment of patients 
with metastatic prostate cancer. We addressed key ques-
tions in each category and proposed evidence-based rec-
ommendations. For categories 1 and 2, levels of evidence 
(LEs) have been described according to the general prin-
ciples of evidence-based medicine (Table 1) [1]. Grades of 
recommendation (GR) were taken into account to deter-
mine (1) quality of evidence; (2) balance between desir-
able and undesirable effects; (3) values and preferences; 
and (4) use of resources. GR were defined as strong rec-
ommendations or weak recommendations [2].
MANAGEMENT OF METASTATIC HOR-
MONE-SENSITIVE PROSTATE CANCER
Key question 1-1: What is the significance of andro-
gen deprivation therapy?
Recommendation LE GR 
The primary treatment for metastatic prostate 
cancer is androgen deprivation therapy 
(surgical castration [bilateral orchiectomy] or 
medical castration based on LHRH agonist), 
which prevents the clinical progression of the 
disease and relieves the symptoms.
1a SR
LHRH antagonist can also be considered as 
the primary treatment for metastatic prostate 
cancer.
2b WR
The growth of mHSPC relies on the androgen recep-
tor (AR) and the androgen signaling pathway; hence, 
androgen deprivation therapy (ADT) is used to treat 
patients with mHSPC [3-6]. In patients with metastatic 
prostate cancer, ADT typically involves surgical castra-
tion (bilateral orchiectomy) or medical castration with 
luteinizing hormone-releasing hormone (LHRH) ago-
nists and antagonists. There is no high-level evidence 
supporting the use of LHRH agonists or orchiectomy 
[7], and LHRH agonists and antagonists provide similar 
efficacy [8]. Medical castration is often preferred due to 
cosmetic and psychological reasons, and due to the fact 
ture trials is necessary and should be applied to the treatment for metastatic prostate cancer patients in the clini-
cal practice. Especially, many prostate cancer patients are old age, have multiple underlying medical comorbidities, 
clinicians should be aware of the significance of medical management as well as clinical efficacy of systemic treat-
ment. 
Keywords: Practice guideline; Prostate neoplasms 
Table 1. Definition of levels of evidence
Level of  
evidence
Definition
1a Systematic reviews (with homogeneity) of 
randomized controlled trials
1b Individual randomized controlled trials (with 
narrow confidence interval) 
1c All or none randomized controlled trials 
2a Systematic reviews (with homogeneity) of cohort 
studies
2b Individual cohort studies or low-quality 
randomized controlled trials
2c Outcomes research or ecological studies 
3a Systematic review (with homogeneity) of case-
control studies
3b Individual case-control studies
4 Case-series (and poor-quality cohort and case-
control studies) 
5 Expert opinion without explicit critical 
appraisal or based on physiology, fundamental 
research, or first principles
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that surgical castration is irreversible. LHRH agonists 
can cause testosterone flare in some patients, worsening 
early clinical symptoms. In patients receiving LHRH ag-
onists, serum testosterone reach castration levels in ap-
proximately 1 to 4 weeks after treatment initiation; thus, 
treatment with antiandrogens for at least 7 days before 
administrating LHRH agonists may be required to pre-
vent the exacerbation of clinical symptoms. In contrast 
to LHRH agonists, LHRH antagonists do not cause a 
testosterone flare and reach castration levels within 3 
days of injection [9].
Key question 1-2: What is the clinical significance of 
docetaxel in mHSPC?
Recommendation LE GR 
Docetaxel should be considered in patients 
with high volume disease who are fit for 
chemotherapy.
1a SR
Docetaxel can be considered in patients 
with low volume disease who are fit for 
chemotherapy.
1a WR
The GETUG-AFU15 [10], CHAARTED [11], and STAM-
PEDE [12] studies evaluated the clinical significance of 
docetaxel in mHSPC patients. GETUG-AFU15 was a 
1:1 randomized phase 3 study that compared the ADT 
plus docetaxel with ADT alone, and the primary end-
point was overall survival (OS). Docetaxel (75 mg/m2, ev-
ery 3 weeks) was administered for up to nine cycles [10]. 
The results revealed that ADT plus docetaxel provided 
longer progression-free survival (PFS) than ADT alone 
(median, 23.5 months vs. 15.4 months; hazard ratio [HR], 
0.75; 95% confidence interval [CI], 0.59 to 0.94; p = 0.015), 
but did not improve OS (median, 58.9 months vs. 54.2 
months; HR, 1.01; 95% CI, 0.75 to 1.36; p = 0.955).
The CHAARTED, a 1:1 randomized phase 3 study 
of 790 patients with mHSPC, compared the ADT plus 
docetaxel with ADT alone, and the primary endpoint was 
OS [11]. Unlike GETUG-AFU15, the results of CHAART-
ED revealed that ADT plus docetaxel provided a longer 
OS than ADT alone (median, 57.6 months vs. 44.0 months; 
HR, 0.61; p < 0.001). Additionally, ADT plus docetaxel im-
proved most secondary endpoints, including the time 
to clinical progression and the time to CRPC. Subgroup 
analysis revealed that the clinical benefit of combination 
therapy was more apparent in patients with high-volume 
disease (HVD; defined as the presence of visceral metas-
tases or ≥ 4 bone lesions with ≥ 1 beyond the vertebral 
bodies and pelvis) than in the overall study population; 
in this subgroup, ADT plus docetaxel provided a sig-
nificantly longer OS than ADT alone (median OS, 49.2 
months vs. 32.2 months; HR, 0.60; 95% CI, 0.45 to 0.81; p 
< 0.001). Severe docetaxel-related adverse events (grade 3 
or higher) were observed in 16.7% of patients. Allergic re-
action, fatigue, diarrhea, stomatitis, and peripheral neu-
ropathy were the most common side effects, and only one 
treatment-related death was reported. A recent long-term 
follow-up study of the CHAARTED cohort confirmed the 
clinical benefits of docetaxel in patients with mHSPC [13].
STAMPEDE was a randomized, multi-arm, controlled 
trial investigating the clinical efficacy of different first-
line treatments in men undergoing long-term hor-
mone therapy as the standard of care (SOC) for newly 
diagnosed locally advanced, metastatic, or recurring 
prostate cancer. The survival outcomes in patients re-
ceiving first-line docetaxel, zoledronic acid, or both in 
combination with hormone therapy were reported in 
2016 [12]. The median OS was 71 months for SOC-only, 
81 months for SOC + docetaxel (HR, 0.78; 95% CI, 0.66 
to 0.93; p = 0.006), and 76 months for SOC + zoledronic 
acid + docetaxel (HR, 0.82; 95% CI, 0.69 to 0.97; p = 0.022). 
Long-term follow-up of the STAMPEDE cohort demon-
strated that ADT plus docetaxel significantly prolonged 
OS, PFS, and failure-free survival (FFS), regardless of the 
disease volume (high or low volume disease) [14].
However, the volume of metastasis and other baseline 
characteristics differed significantly among the patients 
of these studies. Furthermore, the rate of docetaxel-re-
lated deaths was lower in the CHAARTED study than 
in the GETUG-AFU 15 study (1% vs. 7%). The frequency 
of exposure to other treatments (abiraterone, enzalut-
amide, and cabazitaxel) also differed across these stud-
ies. Additionally, most (about 80%) of ADT alone group 
in GETUG-AFU15 study received docetaxel after disease 
progression, which indicating that GETUG-AFU15 trial 
was more a trial of early versus delayed docetaxel [15]. 
Two meta-analysis studies confirmed that the combi-
nation of docetaxel with ADT improved OS in patients 
with mHSPC [16,17]. Therefore, docetaxel administra-
tion should be considered in patients who are suitable 
for chemotherapy, especially in patients with HVD.
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Key question 1-3: What is the clinical significance of 
the androgen receptor-targeted agents?
Recommendation LE GR 
Abiraterone/prednisone, apalutamide or 
enzalutamide (alphabetical) should be 
considered as standard primary therapy in 
mHSPC.
1b SR
The combination of docetaxel with ADT is widely ac-
cepted as the SOC for mHSPC [11,12]. However, because 
many prostate cancer patients are elderly and have 
multiple underlying comorbidities, and are not fit for 
docetaxel, other treatment option is needed in these 
patients. To address the need for further treatment op-
tions in mHSPC, studies have investigated the clinical 
usefulness of androgen receptor-targeted agents (ARTA) 
in mHSPC patients. Abiraterone acetate is a selective 
inhibitor of androgen biosynthesis that potently blocks 
cytochrome P450 c17 (CYP17), a critical enzyme in testos-
terone synthesis, thereby blocking androgen synthesis 
by the adrenal glands and testes and within the pros-
tate tumor [18]. Enzalutamide [19] and apalutamide [20] 
are selective antagonists of the androgen receptor (AR) 
which inhibits AR translocation to the cell nucleus, re-
cruitment of AR cofactors and AR binding to DNA.
LATITUDE was a multinational, 1:1 randomized, dou-
ble-blind, placebo-controlled, phase III trial evaluating 
the efficacy of abiraterone/prednisone combined with 
ADT in men with newly diagnosed high-risk mHSPC. 
The primary endpoints were OS and radiographic pro-
gression-free survival (rPFS). High-risk disease was de-
fined as tumors with at least two of the following charac-
teristics: (1) Gleason score of 8 or higher; (2) at least three 
bone lesions; and (3) presence of measurable visceral me-
tastasis [21]. Patients in the abiraterone group exhibited 
better OS (median OS, not reached [NR] vs. 34.7 months) 
and rPFS (median rPFS, 33.0 months vs. 14.8 months) 
than those in the placebo group (OS [HR, 0.62; 95% CI, 
0.51 to 0.76; p < 0.001], rPFS [HR, 0.47; 95% CI, 0.39 to 0.55; 
p < 0.001]). The superiority of abiraterone over placebo 
was also obvious for all secondary endpoints (time to 
pain progression, time to prostate-specific antigen [PSA] 
progression, time to next symptomatic skeletal event, 
time to chemotherapy, time to subsequent prostate 
cancer therapy). The long-term clinical benefits of abi-
raterone combined with ADT in patients with mHSPC 
have recently been reported [22].
A similar survival benefit of abiraterone/prednisone 
in mHSPC was demonstrated in STAMPEDE [23]. This 
study was a 1:1 random assignment study of 1917 HSPC 
patients comparing the combination of ADT and abi-
raterone/prednisone and ADT alone, about 50% of 
which were metastatic disease. Abiraterone significantly 
improved OS (HR, 0.63; 95% CI, 0.52 to 0.76; p < 0.001) 
and FFS (HR, 0.29; 95% CI, 0.25 to 0.34; p < 0.001). The 
benefit of abiraterone for OS was demonstrated in pre-
planned subgroup analysis of 1002 patients with meta-
static disease at entry (HR, 0.61; 95% CI, 0.49 to 0.75). A 
recent post hoc analysis of the STAMPEDE study was per-
formed to evaluate the heterogeneity of effect between 
LATITUDE high- and low-risk “metastatic” prostate 
cancer patients receiving ADT with abiraterone/pred-
nisone in the STAMPEDE study [24]. The combination 
of ADT with abiraterone/prednisone provided a signifi-
cantly better OS than ADT alone. Heterogeneity of effect 
was not seen between low- and high-risk groups for OS 
or FFS.
The multinational, 1:1 randomized, open-label, phase 
III trial ENZAMET compared the efficacy of early en-
zalutamide and standard nonsteroidal antiandrogens 
(SOC group: bicalutamide, nilutamide, or flutamide) in 
1,125 patients with mHSPC [25]; the primary study end-
point was OS. At the first interim analysis, there were 
102 deaths in the enzalutamide group and 143 deaths 
in the SOC group (HR, 0.67; 95% CI, 0.52 to 0.86; p = 
0.002). Enzalutamide group exhibited superior OS than 
SOC group  (3-year OS rates, 80% vs. 72%). Additional-
ly, enzalutamide significantly improved key secondary 
endpoints, including PSA-PFS (HR, 0.39; p < 0.001) and 
clinical PFS (HR, 0.40; p < 0.001).
The multinational, 1:1 randomized, double-blind, pla-
cebo-controlled, phase III trial ARCHES compared the 
efficacy of enzalutamide combined with ADT to that of 
ADT plus placebo in 1,150 patients with mHSPC; the 
primary study endpoint was rPFS [26]. Compared with 
placebo plus ADT, enzalutamide plus ADT significant-
ly reduced the risk of radiographic progression by 61% 
(HR, 0.39; 95% CI, 0.30 to 0.50; p < 0.001). Median rPFS 
was NR in the enzalutamide group (95% CI, NR to NR) 
versus 19.0 months (95% CI, 16.6 to 22.2) with placebo. 
The superiority of enzalutamide combination treatment 
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was also apparent for key secondary endpoints, includ-
ing the time to PSA progression, the time to initiation of 
new antineoplastic therapy, PSA undetectable rate, and 
objective response rate.
TITAN, a multinational, 1:1 randomized, double-blind, 
placebo-controlled, phase III trial, evaluated the effects 
of combination therapy with apalutamide and ADT on 
rPFS and OS in 1,052 patients with mHSPC [27]. The 
2-year rPFS rates were 68.2% in the apalutamide group 
and 47.5% in the placebo group (HR, 0.48; 95% CI, 0.39 
to 0.60; p < 0.001). The 2-year OS rates were 82.4% in the 
apalutamide group and 73.5% in the placebo (OS: HR, 
0.67; 95% CI, 0.51 to 0.89; p = 0.005).
The ENZAMET, ARCHES, and TITAN studies per-
mitted early docetaxel or included patients who had 
been treated with early docetaxel. In the ENZAMET 
study, the early administration of docetaxel (75 mg/m2, 
every 3 weeks, up to six cycles) was permitted as a strat-
ification factor before randomization. Subgroup analy-
sis revealed a smaller OS benefit of enzalutamide in the 
early docetaxel group (HR, 0.90; 95% CI, 0.62 to 1.31). In 
contrast, the OS benefit of enzalutamide was apparent in 
patients without planned early docetaxel use (HR, 0.53; 
95% CI, 0.37 to 0.75). In the TITAN and ARCHES studies, 
before randomization, patients were stratified based on 
previous early docetaxel use. rPFS improvement after 
treatment with enzalutamide or apalutamide was ob-
served in patients with or without previous docetaxel 
use. However, subgroup analysis of the TITAN cohort 
failed to confirm the benefit of apalutamide on OS (HR, 
1.27; 95% CI, 0.52 to 3.09) in patients who previously re-
ceived early docetaxel. The effects of enzalutamide on 
OS based on previous docetaxel exposure were not re-
ported in the ARCHES study. Currently, the clinical ef-
ficacy of ARTA in patients with mHSPC previously or 
concomitantly treated with docetaxel is unclear.
Key question 1-4: What should be considered in 
determining the treatment of mHSPC?
Recommendation LE GR 
Immediate ADT should be performed to 
prevent disease progression, symptoms and 
complications.
1b SR
Deferred ADT may be considered in patients 
with well-informed asymptomatic patients 
if the risk of treatment related side effects is 
greater than treatment benefits.
2b WR
Abiraterone/prednisone, apalutamide, 
docetaxel, or enzalutamide (alphabetical) 
should be considered as standard primary 
therapy and clinician's judgement is 
important in treatment choice.
1b SR
Determination to start systemic treatment for mHSPC
ADT should be implemented immediately for symp-
tomatic patients. However, the benefit of asymptom-
atic patients from ADT remains controversial due to 
thelack of evidence from well-designed studies which 
were conducted in the era of clinical use of PSA and in-
cluded heterogeneous patients group [28-30]. However, 
considering the poor prognosis of metastatic disease, 
immediate ADT should be considered in metastatic 
patients, even if they are asymptomatic. Deferred ADT 
may be considered for asymptomatic patients if the risk 
of treatment-related side effects is greater than the treat-
ment benefits.
Clinical consideration for determining treatment strategy
Careful consideration is required when deciding a treat-
ment strategy. To date, no large-cohort studies have 
compared the clinical efficacy of cytotoxic chemother-
apy (docetaxel) and ARTA in patients with mHSPC. Ta-
ble 2 summarizes the main characteristics of different 
agents and results of key phase III clinical trials in pa-
tients with mHSPC.
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MANAGEMENT OF METASTATIC CASTRA-
TION-RESISTANT PROSTATE CANCER
Key question 2-1: What should be considered with 
diagnosis of castration resistance?
Recommendation LE GR 
Castration resistant prostate cancer is defined 
as following.
5 SR
Serum testosterone < 50 ng/dL or 1.7 nmol/L 
plus either: 
1.  Three consecutive rises in PSA at least 1 
week apart over the nadir, and a PSA > 2 
ng/mL
2.  Appearance of 2 or more new lesions in 
bone scan or progressive disease using 
RECIST version 1.1
CRPC is defined as disease progression despite effective 
suppression of serum testosterone. The castration level 
of serum testosterone is defined as less than 50 ng/dL or 
1.7 nmol/L. CRPC is defined as castration level of serum 
testosterone plus one of the followings: (1) three consec-
utive rises (over the nadir) in PSA levels at least 1 week 
apart, and a PSA > 2 ng/mL (biochemical progression); 
(2) development of two or more new lesions in bones 
or progressive disease according to Response Evaluation 
Criteria in Solid Tumors (RECIST) version 1.1 [4,5,31-33] 
criteria (radiographic progression). In addition, EAU 
guideline mentions PSA rise resulting two 50% increas-
es over the nadir for biochemical progression. If bone 
lesions are the only indicator of disease progression, at 
least two new lesions should appear in the bone scan 
for a CRPC diagnosis; ambiguous results should be con-
Table 2. Results of four major phase III clinical studies on metastatic hormone-sensitive prostate cancer 
LATITUDE 
(n = 1,199) [21]
TITAN 
(n = 1,052) [27]
CHAARTED 
(n = 790) [11]
ENZAMET 
(n = 1,125) [25]
Agent Abiraterone Apalutamide Docetaxel Enzalutamide
Control Placebo Placebo Placebo Nonsteroidal 
antiandrogen






OS: 0.72 (0.59–0.89) OS: 0.67 (0.52–0.86)
Duration, mo Median OS: NR vs. 34.7
Median rPFS: 33.0 vs. 
14.8
Median OS: NR vs. NR
Median rPFS: NR vs. 
22.1
Median OS: 57.6 vs. 47.2 Median OS: NR vs. NR
Prior ADT, mo Up to 3 Up to 6 Up to 4 Up to 3 
Prior/concurrent 
docetaxel
Exclusion Prior docetaxel (10%) Exclusion Concurrent docetaxel 
(45%)
De novo M1, % 100 80 73 60
Visceral metastases, % 5 12 15 12








Corticosteroid Yes No No No
Population 100% high riskb All 65% High volumesc All 
HR, hazard ratio; CI, confidence interval; OS, overall survival; rPFS, radiographic progression-free survival; NR, not reached; 
ADT, androgen deprivation therapy; AE, adverse event.
a AE of interest: These are AEs of special interest, not most common AEs.
b High risk: At least 2 of 3 high risk criteria (Gleason score of ≥ 8, presence of ≥ 3 lesions on bone scan, presence of measurable 
visceral lesion). 
c High volumes: Visceral metastases (extra-nodal) and/or bone metastases (at least 4 or more bone lesions, one of which must be 
outside of the vertebral column or pelvis).
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firmed by other imaging modalities. For patients who 
develop CRPC, ADT with an LHRH agonist or antago-
nist should be continued to maintain castration level of 
serum testosterone. For patients treated with combined 
androgen blockade, antiandrogens could be discontin-
ued to exclude an antiandrogen withdrawal response. 
Antiandrogen withdrawal response is characterized by 
PSA reduction, occasionally accompanied by a radio-
graphic response, and typically occurs 4 to 6 weeks after 
the discontinuation of first-generation antiandrogen 
therapy [34]. However, if the disease progression is ob-
vious or suspected of rapid progression, this approach 
is not appropriate and should be changed to subsequent 
treatment.
Key question 2-2: What is the clinical significance of 
androgen receptor-targeted agents?
Recommendation LE GR 
Abiraterone/prednisone and enzalutamide 
(alphabetical) are important treatment 
options not only for patients who have 
progressed after docetaxel, but also for 
patients who have not previously received 
docetaxel.
1b SR
Two phase III trials were conducted to evaluate the 
clinical efficacy of abiraterone and enzalutamide in 
patients with metastatic CRPC (mCRPC) who had not 
been previously treated with chemotherapy. The mul-
tinational, 1:1 randomized, double-blind, placebo-con-
trolled, phase III trial COU-AA-302 compared the effects 
of abiraterone plus prednisone to those of placebo plus 
prednisone in 1,088 chemotherapy-naïve patients with 
progressive mCRPC (but no visceral metastasis) who had 
asymptomatic or mildly symptomatic disease; the pri-
mary endpoints were rPFS and OS [35]. No symptoms 
or mild symptoms were defined as follows: (1) Eastern 
Cooperative Oncology Group (ECOG) performance 
status grade of 0–1; or (2) Brief Pain Inventory–Short 
Form (BPI-SF) scores from 0–3. The median rPFS was 
16.5 months in the abiraterone group and 8.3 months 
in the placebo group (HR, 0.53; 95% CI, 0.45 to 0.62; p < 
0.001). Median OS was NR in the abiraterone group and 
was 27.2 months in the placebo group (HR, 0.75; 95% CI, 
0.61 to 0.93; p = 0.01). Notably, abiraterone consistently 
improved rPFS and OS in all prespecified subgroups. A 
preplanned interim analysis of COU-AA-302 evaluating 
patient-reported pain and functional status revealed 
that abiraterone treatment delayed the progression of 
patient-reported pain and deterioration of the quality of 
life [36].
The multinational, 1:1 randomized, double-blind, pla-
cebo-controlled, phase III trial PREVAIL compared the 
clinical efficacy of enzalutamide to that of placebo in 1717 
chemotherapy-naïve patients with progressive mCRPC 
and who had asymptomatic or mildly symptomatic 
disease; the primary endpoints of the study were rPFS 
and OS [37]. In contrast to COU-AA-302, PREVAIL in-
cluded patients with visceral metastasis. No symptoms 
or mild symptoms were defined with the same criteria 
as the COU-AA-302 study (ECOG 0–1, BPI-SF score 0–3). 
The median rPFS (NR vs. 3.9 months) and median OS 
(32.4 months vs. 30.2 months) were longer in enzalut-
amide-treated patients than in patients treated with pla-
cebo (rPFS [HR, 0.19; 95% CI, 0.15 to 0.23; p < 0.001], OS 
[HR, 0.71; 95% CI, 0.60 to 0.84; p < 0.001]). The treatment 
effect of enzalutamide on rPFS and OS was consistent 
across all prespecified subgroups.
Two phase III trials were conducted to evaluate the clin-
ical efficacy of abiraterone and enzalutamide in mCRPC 
patients who had previously undergone chemothera-
py. The multinational, 2:1 randomized, double-blind, 
placebo-controlled, phase III trial COU-AA-301 evalu-
ated the effects of abiraterone plus prednisone in 1,195 
patients with progressive mCRPC who had previously 
been treated with chemotherapy [38]. The primary end-
point was OS. The median OS was 14.8 months in the 
abiraterone plus prednisone group and 10.9 months in 
the prednisone alone group (HR, 0.74; 95% CI 0.64 to 
0.86; p < 0.001). Importantly, abiraterone consistently 
improved OS in all subgroups. Additionally, abiraterone 
improved all secondary endpoints analyzed, including 
the confirmed PSA response rate, the objective response 
rate in patients with measurable disease at baseline, the 
time to PSA progression, and rPFS. The long-term clin-
ical benefits of abiraterone were recently confirmed in a 
longer follow-up study [39].
AFFIRM was a multinational, 2:1 randomized, dou-
ble-blind, placebo-controlled, phase III trial evaluating 
the effect of enzalutamide in 1,199 patients with pro-
gressive mCRPC who had previously undergone chemo-
therapy [40]. The primary endpoint was OS. The median 
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OS was 18.4 months in the enzalutamide group and 13.6 
months in the placebo group (HR, 0.63; 95% CI, 0.53 to 
0.75; p < 0.001). The OS benefit of enzalutamide was con-
sistent across all subgroups. The superiority of enzalut-
amide over placebo was consistent across all secondary 
endpoints, including PSA response rate, soft tissue re-
sponse rate, health-related quality of life, time to PSA 
progression, rPFS, and time to the first skeletal-related 
event.
The adverse events of abiraterone and enzalutamide 
have also been investigated. In COU-AA-301 trial, ad-
verse events associated with CYP17 inhibition and ele-
vated mineralocorticoid levels (fluid retention, edema, 
hypokalemia, and hypertension), cardiac disorders, and 
liver function abnormalities were more common in the 
abiraterone acetate group than in the placebo group 
(55% vs. 43%, p < 0.001). Meanwhile, a higher incidence 
of any grade fatigue, diarrhea, hot flashes, musculoskel-
etal pain, and headache was observed in the enzalut-
amide group than in the placebo group. Notably, the 
AFFIRM study revealed that five of 800 patients (0.6%) 
receiving enzalutamide experienced seizures; some of 
these patients had predisposing conditions or received 
concomitant treatments. Thus, caution should be used 
with patients with a history of seizures, patients receiv-
ing concomitant medication that may lower the seizure 
threshold, and those who have other predisposing fac-
tors, including brain injury, stroke, brain metastases, or 
alcoholism. Additionally, an increased risk of falls was 
observed in older patients treated with enzalutamide 
[41].
Treatment with abiraterone plus prednisone, and 
enzalutamide should be considered for chemothera-
py-naïve patients and those with progressive disease after 
treatment with docetaxel. To date, no studies have di-
rectly compared the safety and efficacy of enzalutamide 
and abiraterone plus prednisone. The differences in their 
mechanisms of action may result in differences in their 
toxicity profiles, and clinicians should carefully consider 
the patient’s underlying diseases and clinical conditions.
Key question 2-3: What is the clinical significance of 
cytotoxic chemotherapy?
Recommendation LE GR 
Docetaxel with prednisone is a standard 
therapy for first line cytotoxic chemotherapy 
in patients with mCRPC
1b SR
Cabazitaxel with prednisone is one of the 
standard therapies in patients with mCRPC 
who have previously received docetaxel.
1b SR
The multinational, 1:1:1 randomized, non-blinded, phase 
III trial TAX327 compared the effects of docetaxel (given 
either every 3 weeks or weekly) plus prednisone with that 
of mitoxantrone plus prednisone in 1,006 patients with 
mCRPC. Patients received 5 mg of prednisone twice dai-
ly and were randomly assigned to receive 75 mg/m2 of 
docetaxel every 3 weeks, 30 mg/m2 of docetaxel weekly 
for 5 of every 6 weeks, or 12 mg/m2 of mitoxantrone every 
3 weeks. OS was the primary endpoint of the study [42]. 
Patients in the 3-week docetaxel group (median OS, 18.9 
months) but not those in the 1-week docetaxel group 
(median OS, 17.4 months) had a longer OS than patients 
in the mitoxantrone group (median OS, 16.5 months). 
There were 166 (50%) deaths (HR, 0.76; 95% CI, 0.62 to 
0.94; p = 0.009) in the 3-week docetaxel group, 190 (57%) 
deaths (HR, 0.91; 95% CI, 0.75 to 1.11; p = 00.36) in the 
weekly docetaxel group, and 201 (60%) deaths in the mi-
toxantrone group. Hair loss (62%), fatigue (53%), diarrhea 
(32%), and grade 3 or 4 neutropenia (32%) were observed 
in patients treated with docetaxel every 3 weeks. A lon-
ger follow-up study of the TAX327 cohort confirmed the 
superiority of docetaxel plus prednisone (every 3 weeks) 
over mitoxantrone plus prednisone in terms of mCRPC 
patient survival [43].
Although the TAX327 study demonstrated the clin-
ical efficacy of 75 mg/m2 docetaxel every 3 weeks, con-
cerns remain regarding the relatively high toxicity 
rates. PROSTY was a multinational, 1:1 randomized, 
non-blinded, phase III trial comparing the effects of 75 
mg/m2 of 3-weekly docetaxel plus prednisone with those 
of 50 mg/m2 2-weekly docetaxel plus prednisone in 361 
patients with mCRPC; the primary endpoint of the 
study was time to treatment failure (TTTF) [44]. The me-
dian TTTF and OS were longer in the 2-weekly group 
than in the 3-weekly group (median TTTF, 5.6 months 
vs. 4.9 months; HR, 1.3; 95% CI, 1.1 to 1.6; p = 0.014) (OS, 
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19.5 months vs. 17.0 months; HR, 1.5; 95% CI, 1.1 to 1.8; p 
= 0.021). Severe adverse events were more frequent in the 
3-weekly docetaxel group than in the 2-weekly docetaxel 
group (neutropenia [HR, 2.3, 95% CI, 1.2 to 4.2; p = 0.007], 
leucopenia [HR, 2.8; 95% CI, 1.0 to 7.6; p = 0.046], infec-
tions with neutropenia [HR, 4.1; 95% CI, 1.1 to 15.4; p = 
0.034]). The findings of this study suggest that 2-weekly 
docetaxel could be a safe option for patients who are not 
suitable for a 3-weekly regimen. The COU-AA-302 [35] 
and PREVAIL [37] studies confirmed the clinical bene-
fit of abiraterone plus prednisone and enzalutamide in 
docetaxel-naïve patients. However, these studies were 
conducted in asymptomatic or minimally symptomat-
ic patients. Therefore, docetaxel remains a important 
treatment option for patients requiring symptom man-
agement and those with visceral metastasis.
Cabazitaxel is an important treatment option for 
mCRPC patients previously treated with docetaxel. 
TROPIC was a multinational, 1:1 randomized, open-la-
bel, phase III trial evaluating the effects of cabazitaxel 
plus prednisone and mitoxantrone plus prednisone in 
755 patients with mCRPC who had progressed during 
or after treatment with a docetaxel-containing reg-
imen. The primary endpoint of the study was OS [45]. 
The median OS was 15.1 months in patients receiving 
cabazitaxel plus prednisone and 12.7 months in patients 
receiving mitoxantrone plus prednisone (HR, 0.70; 95% 
CI, 0.59 to 0.83; p < 0.001). Subgroup analyses of OS con-
sistently favored cabazitaxel group. Additionally, caba-
zitaxel plus prednisone improved most secondary end-
points, including PFS (median PFS, 2.8 months vs. 1.4 
months; HR, 0.74; p < 0.0001), tumor response rate, PSA 
response, and PSA-PFS. However, severe adverse events 
(grade 3 or higher) were more frequent in the cabazitaxel 
group (57.4%) than in the mitoxantrone group (39.4%). 
The most common side effects of cabazitaxel were he-
matological grade 3 or 4 adverse events, including neu-
tropenia, leukopenia, and anemia. The most common 
non-hematological grade 3 or 4 adverse event was diar-
rhea. Peripheral neuropathy (any grade) was observed in 
14% of patients in the cabazitaxel group and in 3% of pa-
tients in the mitoxantrone group. Treatment discontin-
uation due to severe toxicity was required in 18% of pa-
tients in the cabazitaxel group and in 4% of patients in 
the mitoxantrone group. Dose modifications (delay or 
reduction) and prophylactic treatment with granulocyte 
colony-stimulating factor (G-CSF) in high-risk patients 
are potential strategies to mitigate the risk of toxicity.
The PROSELICA study assessed whether 20 mg/m2 
cabazitaxel (C20) was noninferior, in terms of OS, to 
25 mg/m2 cabazitaxel (C25) [46]. The median OS was 13.4 
months in the C20 group and 14.5 months in the C25 
group (HR, 1.024), suggesting that the clinical efficacy of 
C20 and C25 are similar in terms of OS. PSA response 
rates and time to PSA progression were superior in the 
C25 group than in the C20 group. The incidence of most 
severe (grade 3 or higher) adverse effects (e.g., fatigue, 
hematuria, neutropenia, and febrile neutropenia) was 
lower in patients receiving C20 (39.7%) than those re-
ceiving C25 (54.5%). The results of this study suggest that 
cabazitaxel provides a similar clinical benefit at 20 and 
25 mg/m2, while the incidence of manageable grade 3 or 
higher adverse events is relatively low, particularly in pa-
tients receiving 20 mg/m2 cabazitaxel. Thus, 20 mg/m2 
of cabazitaxel could be a feasible treatment option when 
a standard dose of cabazitaxel is unlikely to be tolerated.
FIRSTANA, a multinational, 1:1:1 randomized, open-la-
bel, phase 3 trial designed to demonstrate whether caba-
zitaxel 25 mg/m2 (C25) or 20 mg/m2 (C20) was superior 
to docetaxel 75 mg/m2 (D75) [47]. The median OS was 
24.5 months in the C20 group, 25.2 months in the C25 
group, and 24.3 months in the D75 group. No statistically 
significant differences were observed between the three 
treatment groups in terms of OS, PFS, PSA response, 
and pain response; therefore, the study failed to demon-
strate the superiority of cabazitaxel over docetaxel as a 
first-line treatment. The usefulness of cabazitaxel ad-
ministration before docetaxel treatment remains to be 
demonstrated.
With the treatment options rapidly expanding, many 
studies have investigated the most effective treatment 
sequences. The multicenter, 1:1 randomized, open-label, 
phase III trial CARD compared cabazitaxel with either 
abiraterone or enzalutamide (ARTA) in 255 patients with 
mCRPC who had previously received docetaxel and who 
had disease progression within 12 months while they 
had been receiving alternative ARTA. The primary end-
point of the study was imaging-based progression-free 
survival (iPFS) [48]. The median iPFS was 8.0 months in 
the cabazitaxel group and 3.7 months in the ARTA group 
(HR, 0.54; 95% CI. 0.40 to 0.73; p < 0.001). The clinical 
benefit of cabazitaxel to prolong iPFS was consistent 
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in all prespecified subgroups. The median OS was 13.6 
months in the cabazitaxel group and 11.0 months in the 
ARTA group (HR, 0.64; 95% CI, 0.46 to 089; p = 0.008). 
The incidence of adverse events (any grade) was similar 
in the cabazitaxel group (38.9%) and in the ARTA group 
(38.7%). In this study, prophylactic treatment with G-CSF 
was mandatory during each cycle of cabazitaxel, and se-
vere febrile neutropenia (grade 3 or higher) was observed 
in 3.2% of patients. Therefore, cabazitaxel should be 
considered in patients previously treated with docetaxel 
and ARTA, especially in patients whose tumors rapid-
ly progressed during ARTA treatment. Primary G-CSF 
prophylaxis should also be considered in these patients.
Key question 2-4: What is the clinical significance of 
radium-223 treatment in patients with bone metas-
tasis?
Recommendation LE GR 
Radium-223 can be considered in CRPC 
patients with symptomatic bone metastases 
and no known visceral metastasis.
1b WR
Radium-223 dichloride (radium-223), an alpha emitter, 
selectively targets bone metastases with alpha particles. 
The multicenter, 2:1 randomized, double-blind, place-
bo-controlled, phase III trial ALSYMPCA evaluated the 
efficacy and safety of radium-223 in 921 CRPC patients 
with bone metastasis who had received, were not eligi-
ble to receive, or declined docetaxel. Patients received 
six intravenous injections of radium-223 (50 kBq/kg) or 
matching placebo; one injection was administered ev-
ery 4 weeks. The primary endpoint of the study was OS 
[49]. The median OS was 14.0 months in the radium-223 
group and 11.2 months in the placebo group. Compared 
with placebo, radium-223 treatment was associated with 
a 30% reduction in the risk of death (HR, 0.70; 95% CI, 
0.58 to 0.83; p < 0.001). The effect of radium-223 on OS 
was consistent across all subgroups. All main secondary 
efficacy end points including first symptomatic skele-
tal event provided support for the benefit of radium-223 
over placebo. The frequency of adverse events did not 
differ between the radium-223 and placebo groups.
The multicenter, 1:1 randomized, double-blind, pla-
cebo-controlled, phase III trial ERA223 assessed the 
efficacy and safety of radium-223 and abiraterone plus 
prednisone in chemotherapy-naïve patients with as-
ymptomatic or mildly symptomatic mCRPC (bone 
metastases). Patients received up to six injections of 
radium-223 (55 kBq/kg) or placebo every 4 weeks. The 
primary endpoint of the study was symptomatic skele-
tal event-free survival [50]. Median symptomatic skeletal 
event-free survival was 22.3 months in the radium-223 
group and 26.0 months in the placebo group (HR, 1.122; 
95% CI, 0.917 to 1.374; p = 0.263). The incidence of frac-
ture was higher in the radium-223 group (29%) than in 
the placebo group (11%). Osteoporotic fractures were 
the most common fractures in the radium-223 group 
(49% in radium-223 vs. 17% in placebo). These findings 
suggest that radium-223 may increase the risk of osteo-
porotic fractures. The effects of radium-223 combined 
with enzalutamide and bone-protecting agents, such 
as denosumab and zoledronic acid, are currently under 
clinical investigation. Based on currently available data, 
we do not recommend the combination of radium-223 
with abiraterone plus prednisone, docetaxel, or enzalut-
amide.
Key question 2-5: What is the status of precision 
medicine in prostate cancer?
Recommendation LE GR 
In order for precision medicine to be applied 
to clinical practice, the evidence of accurate 
diagnosis and effective treatment for specific 
genetic alteration are required. Recently, 
many trials targeting BRCA and others are 
ongoing. 
2b WR
Precision cancer treatment based on genomic tumor 
profiling at the point-of-care is transforming the treat-
ment of several cancers, including advanced prostate 
cancer [51]. Recently, several studies on DNA damage re-
pair (DDR) genes have been conducted in prostate can-
cer. Specifically, alterations in DNA repair genes were 
identified in nearly 20% of all primary prostate cancer 
samples. Among these, BRCA1 and BRCA2 alterations 
were found in 1% and 3% of samples, respectively [52]. 
BRCA1/2 alterations have been associated with aggres-
sive tumor phenotypes and poor prognosis [53]. A recent 
study identified genomic defects in DNA repair genes 
in 20% to 30% of advanced CRPC samples; BRCA2 was 
identified as a promising target in mCRPC, being mu-
tated in 10% of mCRPC patients [54].
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The multicenter, open-label, single-group, two-stage, 
phase II study TOPARP-A evaluated the efficacy of 
olaparib as salvage therapy in 50 patients with mCRPC. 
The response rate was the primary endpoint of the study 
[55]. Of the 50 patients, 16 patients (33%) had mutations 
in DDR genes, including BRCA2; 14 of these 16 bio-
marker-positive patients (88%) responded to olaparib, 
but only 6% of biomarker-negative patients exhibited a 
response. OS and rPFS were significantly longer in the 
biomarker-positive group than in the biomarker-nega-
tive group (median OS: 13.8 months vs. 7.5 months, p = 
0.05; median rPFS: 9.8 months vs. 2.7 months, p < 0.001).
The multicenter, open label, investigator-initiated, 
randomized, phase II trial TOPARP B validated the an-
titumor activity of olaparib in 711 patients with mCRPC 
harboring DDR gene alterations. Patients with DDR 
gene alterations were randomly assigned (1:1) into two 
groups, balancing for circulating tumor cell (CTC) count 
at screening. Patients were administered with 400 or 300 
mg olaparib twice daily, given continuously in 4-week 
cycles until disease progression or unacceptable toxici-
ty. Composite response was the primary endpoint of the 
study, and was defined as any of the following: radiolog-
ical objective response by RECIST 1.1; a decrease of 50% 
or more in PSA levels from baseline; or conversion of 
CTC count from ≥ 5 cells per 7.5 mL blood at baseline to 
< 5 cells [56]. In total, 161 (22.6%) patients had DDR gene 
alterations, 98 of whom were randomly assigned and 
treated. Confirmed composite response was observed 
in 54.3% of patients in the 400 mg group and in 39.1% 
of patients in the 300 mg group. Composite response 
rates according to DDR gene alterations were reported 
as 83.3% in BRCA1/2, 36.8% in ATM, 25.0% in CDK12, 
and 57.1% in PALB2.
PROfound was a 2:1 randomized open-label phase III 
trial evaluating the efficacy and safety of olaparib (com-
pared with enzalutamide or abiraterone) in patients 
with mCRPC with genetic alterations in any of 15 pre-
defined homologous recombination repair genes; in all 
patients, the disease had progressed on prior enzalut-
amide or abiraterone treatment [57]. Cohort A included 
patients with alterations in BRCA1, BRCA2, or ATM, 
and cohort B included patients with alterations in any 
of the following genes: BRIP1, BARD1, CDK12, CHEK1, 
CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, 
RAD51D, or RAD54L. Primary endpoint was rPFS in co-
hort A. The median rPFS was 7.4 months in the olaparib 
group and 3.6 months in the control group (HR, 0.34; 
95% CI, 0.25 to 0.47; p < 0.001). The objective response 
rates were 33.3% in the olaparib group and 2.3% in the 
control group. Therefore, PARP inhibition is a promis-
ing option for the treatment of CRPC patients harbor-
ing DDR gene alterations.
Recently, immune checkpoint inhibitors have shown 
promising antitumor effects in various cancers. Several 
ongoing studies are evaluating the efficacy of immu-
notherapy in prostate cancer. The randomized dou-
ble-blind phase III trial CA184-095 investigated the effi-
cacy and safety of ipilimumab as the first-line treatment 
of patients with asymptomatic or minimally symptom-
atic mCRPC without visceral metastases. OS was the 
primary endpoint of the study [58]. Median OS was 28.7 
months in the ipilimumab group and 29.7 months in 
the placebo group. Although ipilimumab did not im-
prove OS, the median PFS was longer in the ipilimum-
ab group than in the placebo group (5.6 months vs. 3.8 
months; HR, 0.67; 95% CI, 0.55 to 0.81).
KEYNOTE-028 was a multicenter, open-label, phase 
Ib trial evaluating the efficacy and safety of pembroli-
zumab in patients with PD-L1-positive advanced solid 
tumors, including 23 patients with prostate adenocar-
cinoma [59]. It revealed that the objective response rate 
in PD-L1-positive patients was 17.4%. KEYNOTE-199, a 
multicohort open-label phase II study, investigated the 
effects of pembrolizumab in 258 patients with mCRPC 
treated with docetaxel and one or more ARTA [60]. The 
objective response rate was 5% in the PD-L1-positive 
group and 3% in the PD-L1-negative group. Numerous 
ongoing studies are investigating the efficacy and safety 
of immune checkpoint inhibitors in prostate cancer.
Key question 2-6: What are the trends in the treat-
ment of non-metastatic CRPC?
Recommendation LE GR 
The ADT should also be maintained in 
patients with non-metastatic CRPC, and 
ARTA (apalutamide, darolutamide and 
enzalutamide, [alphabetically]) can be 
considered in patients with PSADT ≤ 10 
months, and careful observation can be taken 
in patients with PSADT > 10 months.
1b WR
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Non-metastatic castration-resistant prostate cancer 
(M0CRPC) is characterized by PSA progression despite 
primary ADT and the absence of apparent metastatic 
lesions in conventional imaging [61]. The findings of 
several studies suggest that patients with shorter PSA 
doubling time (PSADT) are at greater risk for developing 
metastasis [62,63]. In patients with PSADT of 10 months 
or less, treatment with apalutamide, darolutamide, and 
enzalutamide combined with ADT can be considered.
The international, 2:1 randomized, placebo-con-
trolled, phase III trial SPARTAN evaluated the effect of 
apalutamide on metastasis-free survival (MFS) in 1,207 
men with M0CRPC and PSADT of ≤ 10 months. The 
primary endpoint was MFS, defined as the time from 
randomization to the first detection of distant metas-
tasis or death from any cause (whichever occurred first) 
[64]. The median MFS was 40.5 months in the apalut-
amide group and 16.2 months in the placebo group (HR, 
0.28; 95% CI, 0.23 to 0.35; p < 0.001). The effect of apalut-
amide to prolong MFS was consistent across all prespec-
ified subgroups. The following adverse events occurred 
more frequently in the apalutamide group than in the 
placebo group: fatigue (30.4% vs. 21.1%), rash (23.8% vs. 
5.5%), falls (15.6% vs. 9.0%), fracture (11.7% vs. 6.5%), and 
hypothyroidism (8.1% vs. 2.0%).
PROSPER, an international, 2:1 randomized, pla-
cebo-controlled, phase III trial, evaluated the effect of 
enzalutamide on MFS in 1,401 men with M0CRPC and 
PSADT ≤ 10 months. The primary endpoint of the study 
was MFS [65]. The median MFS was 36.6 months in the 
enzalutamide group and 14.7 months in the placebo 
group (HR, 0.29; 95% CI, 0.24 to 0.35; p < 0.001). The clini-
cal benefit of enzalutamide was consistent across all pre-
specified subgroups. The most common adverse event 
in patients receiving enzalutamide was fatigue. Adverse 
events of special interest that occurred more frequent-
ly (by ≥ 2 percentage points) in the enzalutamide group 
than the placebo group, were hypertension (12% vs. 5%), 
major adverse cardiovascular events (5% vs. 3%), and 
mental impairment disorders (5% vs. 2%). 
The international, 2:1 randomized, placebo-controlled, 
phase III trial ARAMIS investigated the effect of darolut-
amide on MFS in 1,509 patients with M0CRPC and 
PSADT of ≤ 10 months. The primary endpoint of the 
study was MFS [66]. The median MFS was 40.4 months 
in the darolutamide group and 18.4 months in the pla-
cebo group (HR, 0.41; 95% CI, 0.34 to 0.50; p < 0.001). All 
prespecified subgroups benefited from darolutamide 
treatment. The incidence of adverse events was generally 
similar in the darolutamide and placebo groups. Key ad-
verse events that are known to be associated with ARTAs 
including fracture, falls, seizures, and weight loss were 
not different between darolutamide and placebo. 
Meanwhile , for patients with PSADT of > 10 months, 
patients can be closely monitored for disease progres-
sion and development of clinical symptoms [63].
Key question 2-7: What should be considered in 
determining treatment in mCRPC?
Recommendation LE GR 
The decision of treatment should be 
determined comprehensively considering 
their previous treatment history, performance 
status, presence of visceral metastasis, and 
presence of symptoms.
1a SR
In patients without previous docetaxel use
The primary treatments for mCRPC patients without 
previous docetaxel use are docetaxel and abiraterone 
plus prednisone or enzalutamide. To date, no large-co-
hort studies have compared the efficacies of docetaxel, 
abiraterone, or enzalutamide in patients who did not 
previously receive docetaxel; therefore, clinical deci-
sions should be based on a comprehensive evaluation of 
the patient’s symptoms, presence of visceral metastasis, 
and performance status.
Docetaxel is an important primary treatment for pa-
tients with symptomatic mCRPC with or without vis-
ceral metastasis. Docetaxel can be used in patients with 
suspected rapid progression, even in the absence of 
symptoms or visceral metastasis. However, no guide-
lines have been developed regarding docetaxel treat-
ment duration in patients with docetaxel-sensitive tu-
mors. In the TAX327 study [42], patients received up to 
10 cycles of docetaxel. A recent study suggested that the 
continuation of docetaxel chemotherapy for over six 
cycles may provide a survival benefit [67]. However, cli-
nicians should also consider the potential toxicity and 
quality of life impairment associated with prolonged 
docetaxel use.
Enzalutamide and abiraterone plus prednisone are 
also important primary treatments, significantly im-
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proving the survival of patients with asymptomatic or 
minimally symptomatic mCRPC, according to the find-
ings of the COU-AA-302 and PREVAIL studies. Con-
sidering that most mCRPC patients are elderly and 
often have poor performance status, enzalutamide and 
abiraterone plus prednisone may be considered as al-
ternatives to docetaxel in symptomatic patients. After 
progression of abiraterone/prednisone or enzalutamide, 
there is limited study of subsequent therapy. A post hoc 
analysis of the COU-AA-302 cohort evaluated the clinical 
benefit of docetaxel in patients with progressive disease 
after treatment with abiraterone plus prednisone [68]. 
Among 100 patients who received docetaxel as first sub-
sequent therapy, 40% had an unconfirmed PSA decline 
(by ≥ 50%), and 27% had a confirmed PSA decline (by ≥ 
50%). The median duration of docetaxel treatment was 
4.2 months. Docetaxel was the most common first sub-
sequent therapy in that study, but 43% of elderly patients 
and 17% of young patients received no subsequent ther-
apy for mCRPC.
A phase II study assessed the best sequence of abi-
raterone/prednisone and enzalutamide treatment, as 
well as their efficacy as second-line treatment [69]. Pa-
tients were randomly assigned (1:1) to receive either 
abiraterone plus prednisone until PSA progression 
followed by crossover to enzalutamide (group A); pa-
tients in group B received the opposite sequence. The 
primary endpoint was time to second PSA progression, 
defined as the time from first-line therapy initiation 
to confirmed PSA progression on second-line thera-
py or death. The time to second PSA progression was 
longer in group A than in group B (19.3 months vs. 15.2 
months); nevertheless, OS did not differ between the 
two groups. In the patient population that crossed over 
to second-line therapy, the time to PSA progression on 
second-line therapy was 3.5 months in group A and 1.7 
months in group B. Docetaxel may be more appropriate 
option as subsequent therapy after 1st line abiraterone/
prednisone or enzalutamide in patients who are fit for 
chemotherapy.  
In patients with previous docetaxel use
Abiraterone plus prednisone, enzalutamide and caba-
zitax are of clinical benefit in patients with previous 
docetaxel use. In determining subsequent treatment af-
ter docetaxel, the risks and benefits of the treatment, and 
the patient’s quality of life should be taken into careful 
consideration. Meanwhile, docetaxel re-challenge may 
be considered in selected patients with mCRPC. Previ-
ous study investigated the efficacy and tolerance of sub-
sequent treatments (chemotherapy and ARTAs) in pa-
tients treated upfront with docetaxel for mHSPC using 
data from patients included in the GETUG-AFU 15 trial. 
For docetaxel used in first- or second line, a PSA decline 
≥ 50% was observed in 14% who had received upfront 
ADT plus docetaxel [70]. The results of other studies 
suggest that docetaxel re-challenge may be used as sal-
vage therapy in patients with longer re-challenge inter-
val and previous response to docetaxel [71-73]. Therefore, 
docetaxel re-challenge as salvage therapy may be an op-
tion for selected patients. 
Table 3 summarizes the currently available systemic 
treatments for mCRPC.
Table 3. Summary of systemic treatment in mCRPC
In patients with asymptomatic or minimally symptomatic 
mCRPC and with no previous docetaxel treatment
Offer abiraterone or enzalutamide in patients who are 
suitable for these agents 
Offer docetaxel in patients who are suitable for docetaxela
In patients with symptoms or presence of visceral 
metastasis and with no previous docetaxel treatment
Offer docetaxel in patients who are suitable for docetaxel
Offer abiraterone or enzalutamide in patients who are 
suitable for these agentsb
Consider radium-223c
In patients with bone metastases
Offer denosumab or zoledronic acid in mCRPC to 
prevent skeletal-related events
mCRPC, metastatic castration-resistant prostate cancer.
aFor patients who shows signs of rapid progression or visceral 
metastases.
bFor patients who cannot receive or refused docetaxel.
cFor patients with symptomatic bone metastases and without 
visceral metastases, who are not eligible for other treatments.
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CLINICAL CONSIDERATIONS FOR THE TREAT-
MENT OF METASTATIC PROSTATE CANCER
Key question 3-1: What is an appropriate efficacy 
assessment and monitoring of systemic treatment 
in metastatic prostate cancer?
Recommendation
Serum PSA, radiologic imaging (CT/MRI), bone scan, and 
clinical symptoms of the patient should be monitored, 
and the interval and method should be decided according 
to the individual patient's disease status.
Radiologic imaging play an important role in the man-
agement of patients with advanced solid cancer. RE-
CIST is commonly mostly used to evaluate treatment 
responses [32]; however, RECIST criteria are not ideal 
for prostate cancer because bone metastasis is common, 
and measurable lesions are only in 40% of mCRPC cases 
and in 15% of mHSPC cases [74]. Thus, RECIST working 
group suggested that disease and therapy-specific mod-
ifications to RECIST should be considered in prostate 
cancer [33]. Patient monitoring and response evaluation 
in cases of prostate cancer should be conducted com-
prehensively with evaluations of serum PSA levels, ra-
diologic imaging, bone scans, and clinical symptoms.
Efficacy monitoring in patients with mHSPC
Although the majority of patients with mHSPC initial-
ly respond to ADT, most patients progress to mCRPC 
within approximately 1 year. Therefore, it is important 
to monitor the disease progression to mCRPC and de-
termine subsequent therapy accordingly. The effective 
assessment and monitoring methods of pivotal clinical 
trials in mHSPC vary slightly from study to study. 
The LATITUDE study assessed the efficacy of abi-
raterone in patients with mHSPC using sequential ra-
diographic imaging every 4 months, starting at week 
16; imaging modalities included computed tomogra-
phy (CT), magnetic resonance imaging (MRI), and bone 
scans. PSA levels were measured at baseline, monthly in 
the first year, and then every 2 months until the end of 
treatment [21]. The ENZAMET study monitored the effi-
cacy of enzalutamide in patients with mHSPC using CT 
and bone scan performed at baseline and when disease 
progression was suspected. PSA levels were measured at 
baseline, at week 4, and then every 12 weeks until the end 
of treatment [25]. The CHAARTED trial investigated the 
efficacy of docetaxel in patients with mHSPC using PSA 
levels measured at each scheduled visit. CT and bone 
scans were performed at baseline and at the time of doc-
umented castration resistance or as clinically indicated 
[11]. According to the National Comprehensive Cancer 
Network (NCCN) guidelines, a bone scan is recommend-
ed every 6 to 12 months, and soft tissue imaging (CT or 
MRI) is recommended regularly, but no exact interval is 
not mentioned [4].
Considering the above, it is not appropriate to apply 
the same assessment guidelines to all patients. For ex-
ample, frequent disease status assessment with imaging 
is not appropriate for patients with low metastatic bur-
den, a small number of bone lesions, no visceral metas-
tasis, or slow PSA progression. In contrast, patients with 
high metastatic volumes and rapid PSA progression 
require frequent monitoring by serum PSA measure-
ments, radiologic imaging (CT/MRI), bone scans, and 
clinical symptom evaluation; the interval and method of 
monitoring should be decided according to the individ-
ual patient’s disease status. In particular, patients with a 
high disease burden and those with expected rapid pro-
gression should be monitored carefully and frequently.
Efficacy assessment in patients with mCRPC
The RECIST working group suggested that disease-spe-
cific adaptations are needed in prostate cancer because 
imaging-based response evaluation alone is not suffi-
cient given the unique characteristics of prostate, and 
introduced Prostate Cancer Working Group (PCWG) 
criteria in CRPC [33]. Currently, several international 
guidelines [4,5] also discourage disease evaluation using 
imaging methods alone.
We propose that in mCRPC, disease progression is de-
fined as when it meet at least two of the following three 
criteria; PSA progression, radiographic progression, and 
clinical deterioration. For PSA progression, the criteria 
suggested by PCWG2 are most commonly used. For pa-
tients with PSA levels lower than the baseline, PSA pro-
gression should be defined as an increase by ≥ 25% or 
an absolute increase of 2 ng/mL or more from the nadir; 
the increase in PSA levels should be confirmed by 3 or 
more weeks later. For patients whose PSA didn’t decline 
from baseline PSA progression is defined as a 25% or 
greater increase and an absolute increase of 2 ng/mL 
505
Kim IH, et al. Management guidelines for prostate cancer 
www.kjim.orghttps://doi.org/10.3904/kjim.2020.213
or more from the baseline after 12 weeks. Radiographic 
progression is defined as the appearance of two or more 
new lesions in the bone metastases or progressive dis-
ease in soft tissues, lymph nodes, or visceral metastasis 
according to RECIST criteria. Therefore, disease pro-
gression in mCRPC should be confirmed by a compre-
hensive evaluation of PSA levels, imaging findings, and 
clinical symptoms. In general, we recommend that clin-
ical symptoms, PSA levels, and other blood tests should 
be evaluated every 3 to 4 weeks, and CT, MRI, and bone 
scan should be performed every 12 weeks. The interval 
and method may be adjusted based on the individual 
patient’s disease status.
Key question 3-2: What is a proper medical manage-
ment for bone health? 
Recommendation
Denosumab or zoledronic acid should be given to mCRPC 
patients with bone metastases for preventing skeletal 
related events
Prevention and management of osteoporosis induced by 
ADT are required.
Medical management for bone health in patients with 
metastatic prostate cancer differs depending on dis-
ease status. In mCRPC patients with bone metastases 
who are at high risk of skeletal complications, the main 
goal of treatment is to prevent skeletal complications 
and improve prognosis. In mHSPC patients who are 
expected to receive long-term ADT, the main purpose 
of the treatment is to prevent and manage osteoporosis 
induced by ADT.
Management of bone metastases in mCRPC
Bone metastasis occurs in more than 90% of CRPC pa-
tients and is one of the main causes of death, disability, 
poor quality of life, and high treatment costs. A random-
ized, double-blinded, placebo-controlled trial evaluated 
the effects of zoledronic acid in mCRPC patients with 
bone metastases [75]. Patients were randomly assigned 
to receive intravenous zoledronic acid (4 mg) or placebo 
every 3 weeks for 15 months [75]. Skeletal complications 
were less frequent in the zoledronic acid group than in 
the placebo group (33.2% vs. 44.2%, p = 0.021). The me-
dian time to the first skeletal-related event was 321 days 
in the placebo and was NR in the zoledronic acid group 
(p =0.011). OS did not differ between the two groups. 
Long-term treatment with zoledronic acid (4 mg) pro-
vided sustained clinical benefits for mCRPC patients 
with bone metastases [76]. Other bisphosphonate drugs, 
including pamidronate and clodronate, are not recom-
mended for these patients because they do not show sig-
nificant clinical benefit [77,78].
Denosumab is a humanized monoclonal antibody that 
inhibits receptor activator of nuclear factor kappa-Β li-
gand (RANKL) activation and is currently approved for 
the prevention of skeletal-related events in patients 
with bone metastases from solid tumors. The study 
NCT00321620 was an international, double-blinded, 1:1 
randomized, phase III trial comparing the efficacy of 
denosumab to that of zoledronic acid in 1901 CRPC pa-
tients with bone metastases; the primary endpoint of the 
study was time to the first skeletal-related event [79]. Pa-
tients were assigned to receive 120 mg subcutaneous de-
nosumab plus intravenous placebo or 4 mg intravenous 
zoledronic acid plus subcutaneous placebo every 4 weeks. 
Compared with zoledronic acid, denosumab significantly 
delayed the time to the first skeletal-related event by 18% 
(median, 20.7 months vs. 17.1 months; HR, 0.82; 95% CI, 
0.71 to 0.95; p = 0.002). OS did not differ significantly be-
tween the treatment groups. The clinical benefit of zole-
dronic acid and denosumab to prevent skeletal-related 
events has only been demonstrated in CRPC. In mHSPC, 
zoledronic acid did not provide a clinical benefit in terms 
of skeletal-related events [80,81], and no clinical trials 
have assessed the effects of denosumab.
Patients receiving denosumab or zoledronic acid 
should be closely monitored for potential toxicities, 
including osteonecrosis of the jaw and hypocalcemia. 
Osteonecrosis of the jaw is a relatively uncommon but 
potentially serious side effect. Dental health evaluation 
should be conducted before treatment with denosumab 
or zoledronic acid because the risk of osteonecrosis of the 
jaw is increased by previous dental trauma, infections, or 
dental surgery [82,83]. Hypocalcemia is a major concern 
in patients treated with denosumab or zoledronic acid. 
Serum calcium levels should be measured before treat-
ment and should be monitored throughout the treat-
ment. Daily oral calcium and vitamin D supplement are 
recommended in all patients except those with hypercal-
cemia [84].
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Management of ADT-induced osteoporosis
ADT significantly impairs bone health, decreasing bone 
mass density and increasing the risk of fractures [85]. 
ADT is known to increase the risk of fractures from 21% 
to 54%, and long-term ADT is strongly associated with a 
high risk of fractures [86,87]. NCCN guideline for pros-
tate cancer [4] recommends that supplement of calcium 
(1,000 to 1,200 mg, daily) and vitamin D3 (400 to 1,000 
IU, daily) for patients undergoing ADT and additional 
treatments in patients over the age of 50 with T score 
between –1.0 and –2.5 at the femoral neck, total hip, or 
lumbar spine by the dual energy X-ray absorptiometry 
(DEXA), and the risk of a 10-year hip fracture is 3% or 
greater or the risk of a major osteoporosis-related frac-
ture is 20% or greater calculated by the Fracture Risk 
Assessment Tool (FRAX) algorithm.
In prostate cancer patients receiving ADT, bisphos-
phonates increase bone mineral density, a surrogate 
marker for bone fractures [88,89]. A randomized phase 
III study revealed that denosumab treatment in patients 
receiving ADT for non-metastatic prostate cancer was 
associated with increased bone mineral density at all 
sites and a reduction in the incidence of new vertebral 
fractures [90]. The Korean Society for Bone and Mineral 
Research recommends the administration of alendro-
nate (oral, 70 mg, weekly), zoledronic acid (intravenous, 
5 mg, annually), and denosumab (subcutaneous, 60 
mg, every 6 months) in patients who are at high risk of 
ADT-induced fractures.
Key question 3-3: What is the role of radiotherapy in 
bone metastasis?
Recommendation
Radiotherapy provides relief of pain induced by bone 
metastasis 
Bone metastasis is usually associated with overstimu-
lation of osteoclasts and osteoblasts. Pain is common 
among patients with bone metastasis due to tumor-in-
duced disruption of the balance between osteoclasts and 
osteoblasts, tumor-induced nerve damage, production 
of factors causing nerve irritation, and tumor-induced 
muscle spasms. Radiotherapy relieves pain by reducing 
the activity of osteoclasts, inflammatory cells, and chem-
ical mediators, in addition to reducing the size of the 
tumor [91-93].
Several randomized trials have demonstrated that ra-
diotherapy can relieve pain. The Radiation Therapy On-
cology Group trial 97-14 was a prospective phase III trial 
investigating whether radiotherapy (8 Gy delivered in a 
single treatment fraction) provided pain and narcotic re-
lief similar to that of standard treatment (30 Gy delivered 
in ten treatment fractions over 2 weeks) [94]. The results 
revealed that both regimens were equivalent in terms of 
pain and narcotic relief within 3 months and were well 
tolerated with few adverse effects. The non-blinded, 
randomized, controlled trial NCT00080912 confirmed 
that treatment with 8 Gy in a single fraction was non-in-
ferior and less toxic than 20 Gy delivered in multiple 
fractions [95].
Patients who have been responding to radiotherapy 
can also experience pain due to disease progression. 
Several studies which investigated the delivery of reirra-
diation to the same site of painful bone metastases have 
demonstrated that pain response rates was up to 50% 
[96]. Another meta-analysis reported that pain response 
after reirradiation was achieved in 58% of patients [97]. 
Therefore, re-irradiation of radiation-refractory bone 
pain can be used in selected patients.
Key question 3-4: What are the adverse effects of 
ADT?
Recommendation
ADT induces several adverse effects including hot flashes, 
osteoporosis, fatigue, depression, erectile dysfunction, 
gynecomastia, obesity, diabetes, cardiovascular disease. 
Therefore, the management of adverse effects should be 
needed.
Hot flashes are one of the most common symptomat-
ic side effects associated with ADT. Up to 80% of pa-
tients receiving LHRH agonists experience hot flashes 
[98]. Hot flashes mostly occur about 3 months after ADT 
initiation, and long-term hot flashes significantly affect 
quality of life [99]. Although treatment with estrogen re-
ceptor modulators or low dose estrogen (e.g., 0.5 mg/day) 
can relieve symptoms, this increases the risk of cardio-
vascular complications [100]. 
Sexual dysfunction is also very common, occurring in 
up to 90% of patients receiving ADT. Efforts to mitigate 
sexual dysfunction using phosphodiesterase 5 inhib-
itors and vacuum-assisted devices have shown limited 
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efficacy [99].
Gynecomastia is observed in approximately 25% of 
patients receiving ADT, significantly affecting psycho-
logical wellbeing and quality of life, as well as induc-
ing breast pain. For patients with severe gynecomastia, 
treatment with tamoxifen and irradiation may be con-
sidered. Tamoxifen is more useful as primary preven-
tion, and irradiation can improve gynecomastia that has 
already occurred [101,102]. 
The bone-related adverse effects of ADT are discussed 
above in key question 3-2.
Cardiovascular disease and diabetes are the most 
common causes of death induced by adverse events of 
ADT, and it is even known to exceed prostate cancer it-
self as a cause for death among prostate cancer patients 
[103-105]. Many studies have evaluated the relationship 
between ADT and cardiovascular diseases. One obser-
vational population-based study found that the use of 
LHRH agonists was associated with an increased risk of 
diabetes, coronary heart disease, myocardial infarction, 
and sudden cardiac death. A large meta-analysis pub-
lished in 2015 reported that ADT increased the risks of 
myocardial infarction, non-fatal cardiovascular diseas-
es, and stroke [106]. However, several other studies have 
found no relationship between ADT and cardiovascu-
lar diseases [28,105,107-113]. Some studies have found an 
association between ADT and death due to cardiovas-
cular disease only in patients with known risk factors 
or a history of cardiovascular disease [108,114,115]. The 
American Heart Association (AHA), the American Can-
cer Society, and the American Urologic Association have 
published guidelines regarding the management of risk 
factors [116]. AHA suggests the Awareness & Aspirin, 
Blood pressure, Cholesterol & Cigarette, Diet & Diabe-
tes, and Exercise (ABCDE) method for prostate cancer 
survivors [117].
Neurocognitive impairments have also been reported 
in patients receiving ADT [118]. A large-cohort study re-
ported a significant relationship between ADT and risk 
of dementia [119]. The results regarding the relationship 
between ADT and cognitive function are conflicting 
[120-124]. Nevertheless, the possibility of cognitive im-
pairment should be taken into account before starting 
ADT, especially in patients with underlying neurocog-
nitive disorders.
Key question 3-5: What is the diagnosis and treat-
ment of small cell/neuroendocrine prostate cancer?
Recommendation
Small cell/neuroendocrine prostate cancer should 
be considered when patients showed rapid disease 
progression with high metastatic burden, high prevalence 
osteolytic bone metastases, despite of low serum PSA 
level. Biopsy should be considered when small cell/
neuroendocrine prostate cancer is suspected.
Primary small cell/neuroendocrine prostate cancer is 
an very rare yet aggressive disease. Treatment-related 
small cell/neuroendocrine prostate cancer (t-NEPC) is 
more common than primary small cell/neuroendocrine 
prostate cancer. Long-term ADT is associated with an 
increased risk of small cell/neuroendocrine prostate 
cancer [125,126]. Small cell/neuroendocrine prostate 
cancer has a unique clinical presentation, including a 
short-term or no response to ADT, rapid progression, 
high prevalence of lytic bone lesions, presence of viscer-
al metastases, a markedly enlarged prostate, serum neu-
roendocrine markers (chromogranin A, synaptophysin, 
neuron-specific enolase) and low PSA level relative to 
disease burden [127,128]. A prospective study of metastat-
ic tumor biopsies found an overall t-NEPC incidence of 
17% [129]. Notably, t-NEPC was associated with inferior 
OS in patients treated with abiraterone or enzalutamide 
for mCRPC (HR, 2.02; 95% CI, 1.07 to 3.82). Interestingly, 
genomic alterations in DDR genes were nearly mutually 
exclusive with t-NEPC differentiation. When small cell/
neuroendocrine prostate cancer is suspected, a biopsy of 
accessible sites should be considered to identify patients 
with NEPC pathological features and require disease 
management [127,130].
Currently, no standard treatment has been established 
for small cell/neuroendocrine prostate cancer. Patients 
diagnosed with small cell/neuroendocrine prostate 
cancer are often treated with platinum-based cytotoxic 
chemotherapy (e.g., cisplatin plus etoposide, carbopla-
tin plus etoposide, or docetaxel plus carboplatin), which 
are also often used in patients with small-cell lung can-
cer [131]. A recent phase II study compared the clinical 
efficacy of cabazitaxel in combination with carboplatin 
to that of cabazitaxel monotherapy in mCRPC patients 
with histological evidence of prostate adenocarcinoma, 
small-cell prostate carcinoma, or both [132]. This study 
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conducted molecular profiling of tumor biopsy which 
showed virulent, atypical clinical features, defined them 
as aggressive variant prostate cancer molecular sig-
nature (AVPC-MS) composed of combined defects in 
at least two of the three tumor suppressors TP53, RB1, 
and PTEN, and then performed sub-group analysis. 
Patients with AVPC-MS who received cabazitaxel plus 
carboplatin had a significantly longer PFS than those 
treated with cabazitaxel alone (median PFS, 7.5 months 
vs. 1.7 months, p = 0.017). Additionally, OS was longer in 
patients treated with cabazitaxel plus carboplatin than 
those treated with cabazitaxel monotherapy (median OS, 
20.2 months vs. 8.5 months, p = 0.0002). These results 
suggest that platinum-based chemotherapy may be a 
feasible treatment option for patients with small cell/
neuroendocrine prostate cancer.
CONCLUSIONS
The treatment landscape of metastatic prostate cancer 
is changing rapidly, and numerous trials are ongoing to 
identify novel therapies for patients with metastatic pros-
tate cancer. It is necessary to verify the results of clini-
cal studies. Given that many patients with prostate can-
cer are elderly or have multiple underlying conditions, 
clinicians should carefully consider the clinical efficacy 
and safety of systemic treatments. Based on emerging ev-
idence from clinical studies, we will continue to update 
the Korean guidelines for the management of metastatic 
prostate cancer.
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